COVID-19 and Vaccination Impact on Liver Injury Detection During Clinical Trials

Strategic Insights -

Researchers at Genentech Inc. in collaboration with the IQ DILI Initiative have proposed recommendations for the evaluation of elevated liver tests due to COVID-19, its treatments, and COVID-19 vaccination. The study noted that liver-related manifestations in non-hospitalized patients with COVID-19 are highly varied and can occur after symptoms resolve and testing is negative. Treatments for COVID-19 may cause liver injury or alter pharmacokinetics, and COVID-19 vaccination has been associated with rare but clear hepatotoxicity.

Key Takeaways:

  • The IQ DILI Initiative proposes recommendations to address the lack of guidance for evaluation of elevated liver tests due to COVID-19, its treatments, and COVID-19 vaccination.
  • Liver-related manifestations in non-hospitalized patients with COVID-19 are highly varied and can occur after symptoms resolve and testing is negative.
  • Treatments for COVID-19 may cause liver injury or alter pharmacokinetics.
  • COVID-19 vaccination has been associated with rare but clear hepatotoxicity, typically consistent with drug-induced autoimmune-like hepatitis.
  • Drug developers and investigators should be aware of the potential liver-related manifestations related to COVID-19, its treatments, and COVID-19 vaccination.

Statistics:

  • The study concluded that since clinical trial participants may not consider vaccinations in their medical history, specific inquiry about their receipt is important when liver tests are abnormal during screening and as part of DILI causality assessment.
  • The IQ DILI Initiative consists of experts from academia, regulatory agencies, and industry.
  • The study highlighted the need for consideration of COVID-19 testing as part of DILI causality assessment, as a positive test may prevent premature termination of the investigational drug.

Sources:

  • The Impact of Covid-19 and Covid-19 Vaccination On Detection, Assessment, and Management of Suspected Acute Drug-induced Liver Injury Occurring During Clinical Trials: Consensus Recommendations From the Iq Dili Initiative. Drug Safety, 2025.
  • Genentech Inc. (Early Dev Safety, South San Francisco, CA 94080, United States)
  • Adis Int Ltd, 5 The Warehouse Way, Northcote 0627, Auckland, New Zealand
  • Vaccine Weekly, October 29, 2025; p 411.